In recent years, the incidence of pneumonia caused by multidrug-resistant (MDR) Gram-negative bacteria (G−) has increased year by year. Polymyxin B has a good clinical effect in the treatment of MDR, but there is controversy about the administration route of this drug. In this study, we retrospectively analyzed the clinical data of 84 cases of MDR Gram-negative bacterial pneumonia, and aimed to explore the effects of aerosol inhalation combined with intravenous polymyxin B infusion on the bacterial clearance, symptom improvement, and serum infection indexes of MDR patients on the patients with Gram-negative (G−) bacterial pneumonia. The results show that aerosol inhalation combined with intravenous drip of polymyxin B can improve bacterial clearance rate, reduce levels of serum inflammatory factors, and improve clinical symptoms in patients with pneumonia induced by MDR G-bacteria.

中文翻译：

---

雾化吸入联合静脉滴注多粘菌素B对多重耐药革兰氏阴性菌肺炎患者细菌清除、症状改善及血清感染指数的影响

近年来，耐多药（MDR）革兰氏阴性菌（G-）引起的肺炎发病率逐年上升。多粘菌素B在治疗MDR方面具有良好的临床效果，但该药的给药途径存在争议。本研究回顾性分析了84例耐多药革兰氏阴性细菌性肺炎的临床资料，旨在探讨雾化吸入联合静脉滴注多粘菌素B对耐多药细菌清除、症状改善及血清感染指标的影响。对革兰氏阴性患者（G−) 细菌性肺炎。结果表明，雾化吸入联合静脉滴注多粘菌素B可提高MDR G-菌所致肺炎患者的细菌清除率，降低血清炎性因子水平，改善临床症状。